Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...
Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...
This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...
Alector (NASDAQ:ALEC) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the ...
The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...
Bay Area biopharmaceutical company Alector, Inc. is cutting dozens of jobs after the reported flop of its most recent drug trial. According to a Worker Adjustment Retraining ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...
The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while ...
Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...
Alector said it will cut its workforce nearly in half after discontinuing trials for latozinemab, an investigational treatment for dementia. The biopharmaceutical company said it would reduce its ...
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback